Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
378 SEK | +17.76% | +14.79% | +14.26% |
Sales 2024 * | 794M 72.99M | Sales 2025 * | 1.07B 98.79M | Capitalization | 10.11B 929M |
---|---|---|---|---|---|
Net income 2024 * | 70M 6.43M | Net income 2025 * | 158M 14.52M | EV / Sales 2024 * | 12.2 x |
Net cash position 2024 * | 454M 41.68M | Net cash position 2025 * | 476M 43.75M | EV / Sales 2025 * | 8.96 x |
P/E ratio 2024 * |
154
x | P/E ratio 2025 * |
67.2
x | Employees | 160 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.13% |
Latest transcript on Xvivo Perfusion AB
1 day | +17.76% | ||
1 week | +14.79% | ||
Current month | +36.91% | ||
1 month | +37.16% | ||
3 months | +14.79% | ||
6 months | +62.99% | ||
Current year | +14.26% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 12-08-31 | |
Director of Finance/CFO | 39 | - | |
Chief Tech/Sci/R&D Officer | 57 | 20-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Camilla Öberg
BRD | Director/Board Member | 60 | 16-04-30 |
Chairman | 65 | - | |
Lars Henrikson
BRD | Director/Board Member | 69 | 19-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 376.5 | +17.29% | 212 936 |
24-04-23 | 321 | +2.23% | 30,602 |
24-04-22 | 314 | -0.79% | 23,587 |
24-04-19 | 316.5 | -1.40% | 27,963 |
24-04-18 | 321 | -2.13% | 41,987 |
Delayed Quote Nasdaq Stockholm, April 24, 2024 at 07:24 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.26% | 934M | |
-2.25% | 187B | |
-1.32% | 108B | |
-3.92% | 67.71B | |
+7.99% | 53.07B | |
+15.74% | 47.36B | |
+6.01% | 39.73B | |
+10.81% | 28.56B | |
+2.34% | 26.55B | |
+15.97% | 25.13B |
- Stock Market
- Equities
- XVIVO Stock